ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξγεεηϊ δϊεφΰεϊ μψαςεο δψΰωεο ωμ 2006 δϊεφΰεϊ λεμμεϊ μψΰωεπδ ΰϊ IVAX10/5/2006
δξλιψεϊ αψαςεο ςμε α- 28% εδρϊλξε α- 1,672 ξμιεο $.
δτργ ξγεεη ωμ 1,009 ξμιεο $ εδτργ μξπιδ ωμ 1.40$ δξωχτιν δεφΰεϊ ηγ-τςξιεϊ δχωεψεϊ μηωαεπΰεϊ δψλιωδ ωμ IVAX.
ψεεη πχι ξεϊΰν μψαςεο δψΰωεο (μτπι δεφΰεϊ ηγ-τςξιεϊ)* ωμ 286 ξμιεο $, βιγεμ ωμ 10%, ψεεη μξπιδ ξεϊΰν* αγιμεμ ξμΰ ωμ 0.37$
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ γιεεηδ διεν ςμ ϊεφΰεϊ δψαςεο δψΰωεο ωδρϊιιν α- 31 αξψυ, 2006, δψαςεο δξγεεη δψΰωεο ξΰζ δωμξϊ ψλιωϊ IVAX α- 26 αιπεΰψ, 2006. ϊεφΰεϊ ΰμδ λεμμεϊ μψΰωεπδ ΰϊ ϊεφΰεϊιδ ωμ IVAX, ξΰζ 1 αταψεΰψ, 2006.
δϊεφΰεϊ ωμ δψαςεο δψΰωεο, ςμ τι λμμι ηωαεπΰεϊ ξχεαμιν αΰψδ"α (US GAAP), δλεμμεϊ ξηιχϊ 1.2 ξιμιΰψγ $ αβιο ξε"τ αϊδμικ ε- 64 ξμιεο $ αβιο ωιςψεκ ξμΰι δχωεψιν μψλιωϊ IVAX, ξρϊλξεϊ μδτργ ωμ 1,009 ξμιεο $, ΰε 1.40$ μξπιδ. θας ξΰξιπδ λι δφβϊ πϊεπιν μτπι δδεφΰεϊ δηγ-τςξιεϊ αψαςεο δψΰωεο ωμ 2006, ξωχτϊ πλεο ιεϊψ ΰϊ δξβξεϊ ατςιμεϊ δηαψδ. ψεεη πχι ξεϊΰν (μτπι δεφΰεϊ ηγ-τςξιεϊ)* μψαςεο δψΰωεο δρϊλν α- 286 ξμιεο $, βιγεμ ωμ 10% μςεξϊ δψαςεο δξχαιμ ΰωϊχγ εψεεη μξπιδ ξεϊΰν* αγιμεμ ξμΰ, δρϊλν α- 0.37$, αδωεεΰδ μ- 0.38$ αψαςεο δξχαιμ ΰωϊχγ.
αδϊΰν μλμμι δ- US GAAP, θας δημδ μψωεν δεφΰεϊ αβιο ΰετφιεϊ μςεαγιν αψαςεο δψΰωεο ωμ 2006. δδτργ δξγεεη δξγεμμ μξπιδ εδψεεη μξπιδ δξεϊΰν αγιμεμ ξμΰ, λεμμιν ωπιδν δεφΰδ ωμ λ- 1 ρπθ μξπιδ δχωεψιν μδωτςδ ζε.
ιωψΰμ ξχεα, πωιΰ εξπλ"μ θας, δβια ςμ δϊεφΰεϊ:"ΰπε ξΰγ ξψεφιν ξδϊεφΰεϊ ωμ ψαςεο ξιεηγ ζδ, αε δϊημπε αϊδμικ δΰιπθβψφιδ ωμ IVAX αθας, εΰσ δφμηπε μδωιβ δϊχγξεϊ ξψωιξδ. διεν, διχτδ, βεγμδ ετψιρϊδ δβιΰεβψτιϊ ωμ θας, ΰωψ ΰιο ωπι μδν αϊςωιιδ, ξΰτωψιν μπε μϊϊ ςψκ ιεφΰ γετο μηεμιν, μμχεηεϊιπε εμαςμι δξπιεϊ ωμπε".
ξψ ξχεα δερισ:" ψαςεο ζδ διδ θεα αξιεηγ ςαεψ δχετχρεο®, ΰωψ ξξωικ μωαεψ ωιΰι ξλιψεϊ εμφξεη αχφα ξδιψ ιεϊψ ξχφα δφξιηδ ωμ ωεχ δθψωϊ δπτεφδ (MS) δβμεαμι. ΰπε πμδαιν ξδδζγξπειεϊ δθξεπεϊ αωπϊ 2006 εΰπε ξΰξιπιν ωϊδιδ ζε ωπδ ξφειπϊ μθας."
δξλιψεϊ πθε αψαςεο δψΰωεο βγμε α- 28% αδωεεΰδ μψαςεο δξχαιμ αωπδ ωςαψδ εδρϊλξε α- 1,672 ξμιεο $ εζΰϊ μΰηψ δωτςδ ωμιμιϊ ωμ ωςψι ημιτιο αρκ ωμ 39 ξμιεο $. ξλιψεϊ IVAX ΰωψ λμεμεϊ αρλεν ζδ δρϊλξε α- 329 ξμιεο $.
δξλιψεϊ δτψξφαθιεϊ αφτεο ΰξψιχδ (λεμμ χετχρεο®) διεε 57% ξρκ λμ δξλιψεϊ δτψξφαθιεϊ ωμ δηαψδ εδρϊλξε α- 851 ξμιεο $ αψαςεο, αδωεεΰδ μ- 730 ξμιεο $ αψαςεο δψΰωεο ωμ 2005, βιγεμ ωμ 17%. δξλιψεϊ δεωτςε μθεαδ αψαςεο δψΰωεο ξδλμμϊ 2 ηεγωι ξλιψεϊ ωμ IVAX, ξξλιψεϊιδν ωμ 23 ξεφψιν ηγωιν ωμΰ πξλψε αψαςεο δξχαιμ ΰωϊχγ, λωδςιχψιν αιπιδν δν azithromicin ε- fexofenadine, εξβιγεμ αξλιψεϊ δχετχρεο®. πλεο μ- 1 αξΰι, 2006, μθας 151 αχωεϊ δξξϊιπεϊ μΰιωεψ ρετι ωμ ψωεϊ δξζεο εδϊψετεϊ δΰξψιχΰιϊ (FDA). ρκ δξλιψεϊ δωπϊιεϊ ωμ αχωεϊ ΰμδ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, διπε λ- 92 ξμιΰψγ $. θας ξΰξιπδ λι διπδ δψΰωεπδ μδβιω αχωδ μΰιωεψ ςαεψ 52 ξεφψιν ξϊεκ αχωεϊ ΰμδ, δξωχτιν ξλιψεϊ ωπϊιεϊ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, ωμ ξςμ μ- 39 ξμιΰψγ $.
δξλιψεϊ δτψξφαθιεϊ αΰιψετδ (λεμμ χετχρεο®) ΰωψ διεε 26% ξρκ λμ δξλιψεϊ δτψξφαθιεϊ ωμ δηαψδ, βγμε α- 17% αψαςεο εδρϊλξε α- 381 ξμιεο $. δβιγεμ πεας ξδδερτδ ωμ ξλιψεϊ IVAX (ωμ ηεγωιιν), ξξλιψεϊ βπψιεϊ βαεδεϊ ιεϊψ εξβιγεμ αξλιψεϊ δχετχρεο®.
χετχρεο® - δξλιψεϊ δβμεαμιεϊ ωμ χετχρεο®, αξεπηι ξηιψ ξλιψδ μωεχ, δρϊλξε αψαςεο ζδ α- 329 ξμιεο $, βιγεμ ωμ 29% αδωεεΰδ μψαςεο δξχαιμ α- 2005, δξξχξεϊ ΰϊ χετχρεο® λθιτεμ δωπι αβεγμε αςεμν μθψωϊ πτεφδ αξεπηι ξλιψεϊ. δξλιψεϊ αΰψδ"α αξεπηι ξηιψ ξλιψδ μωεχ αψαςεο δψΰωεο βγμε α- 36% εδρϊλξε α- 221 ξμιεο $. δξλιψεϊ αξεπηι ξηιψ ξλιψδ μωεχ ξηευ μΰψδ"α, αςιχψ αΰιψετδ εχπγδ, βγμε α- 17% εδρϊλξε α- 108 ξμιεο $.
®Azilect - ξωεεχ λςϊ αςωψδ ωεεχιν ΰψετΰιν εδϊδμικ ωμ δλμμϊ ®Azilect αψωιξϊ δξεφψιν δλμεμιν αρμ δϊψετεϊ ξξωικ αλξδ ξδωεεχιν αδν δεωχ λξε βν αωεεχιν περτιν.
ξλιψεϊ δλιξιδ (API) λεμμ ξλιψεϊ τπιξιεϊ μςρχιδ δτψξφαθιιν ωμ θας, δρϊλξε α- 368 ξμιεο $, βιγεμ ωμ 45% μςεξϊ δψαςεο δψΰωεο α- 2005. ξλιψεϊ δ- API μφγγιν ωμιωιιν δρϊλξε α- 149 ξμιεο $, βιγεμ ωμ 26% μςεξϊ δψαςεο δξχαιμ ΰωϊχγ. ςιχψ δβιγεμ αξλιψεϊ τπιξιεϊ ξωχσ δψηαδ ωμ δΰιπθβψφιδ δΰπλιϊ, εατψθ αλμ δχωεψ μδιςψλεϊ μχψΰϊ δωχεϊ ωμ ξεφψιν βγεμιν ΰωψ φτειεϊ μδϊηιμ αξδμκ δψαςεο δωπι ωμ 2006.
ωιςεψ δψεεη δβεμξι δξεϊΰν (μΰηψ πιθψεμ δωιςψεκ δηγ-τςξι ωμ δξμΰι ωμ IVAX ωδβγιμ ΰϊ δδεφΰεϊ δψαςεο) δβις μ- 47.1% αψαςεο δψΰωεο αδωεεΰδ μωιςεψ ψεεη βεμξι ωμ 46.3% αψαςεο δψΰωεο ωμ 2005 εωμ 47.2% αωπϊ 2005 λεμδ.
δεφΰεϊ ξηχψ ετιϊεη (ξε"τ) πθε (μΰηψ δωϊϊτεϊ φγγιν ωμιωιν) βγμε α- 17% εδρϊλξε α- 103 ξμιεο $ (6.1% ξξλιψεϊ πθε) εξωχτεϊ αςιχψ ΰϊ δερτϊ δεφΰεϊ δξε"τ ωμ IVAX.
δεφΰεϊ ξλιψδ, δπδμδ ελμμιεϊ (SG&A) διεε 18.9% ξδξλιψεϊ πθε εδρϊλξε α- 316 ξμιεο $ αψαςεο δψΰωεο ωμ 2006, αδωεεΰδ μ- 14.1% ξρκ δξλιψεϊ πθε ε- 185 ξμιεο $ αψαςεο δψΰωεο ωμ 2005. ϊεφΰεϊ βαεδεϊ ΰμδ ξωχτεϊ ΰϊ δλμμϊο ωμ δεφΰεϊ SG&A ωμ IVAX ωωιςεψο βαεδ ιεϊψ αωμ δξωχμ δβαεδ ωμ τςιμεϊδ αϊηεν ϊψετεϊ δξεϊβ εαωεεχιν δξΰετιιπιν αβπψιχδ ξξεϊβϊ, λξε βν ψιωεν μψΰωεπδ ωμ δεφΰεϊ αβιο ΰετφιεϊ μςεαγιν εημεχϊ ψεεηιν ςν ωεϊσ.
ωιςεψ δξρ ωπχας αψαςεο ζδ ωμ 19% ξιιφβ ΰϊ δςψλϊπε δπεληιϊ λι ιδιδ ζδ ωιςεψ δξρ ωμ ωπϊ 2006 λεμδ αδωεεΰδ μ- 18% αωπϊ 2005 λεμδ. ωιςεψ ζδ ξωχσ ϊξδιμ δλπρεϊ ωεπδ λξε βν ωιςεψι ξρ βαεδιν ιεϊψ ωμ IVAX.
ϊζψιν δξζεξπιν ξτςιμεϊ ωεθτϊ αψαςεο δψΰωεο ωμ 2006 δρϊλν α- 288 ξμιεο $. ωεει ξζεξπιν
επιιψεϊ ςψκ ρηιψιν μιεν 31 αξψυ, 2006 διδ 1.5 ξμιΰψγ $.
δδεο δςφξι ωμ θας δρϊλν α- 31 αξψυ, 2006, α- 9.2 ξμιΰψγ $, βιγεμ ωμ 3.2 ξμιΰψγ $ μςεξϊ 31 αγφξαψ, 2005 αςιχψ λϊεφΰδ ξδπτχϊ ξπιεϊ μαςμι δξπιεϊ ωμ IVAX, απιλει δδτργ δξγεεη μψαςεο.
ξρτψ δξπιεϊ - πλεο μψαςεο δψΰωεο ωμ 2006, ξρτψ δξπιεϊ μφεψκ ηιωεα δψεεη δπχι μξπιδ αγιμεμ ξμΰ, διπε 788 ξμιεο ξπιεϊ.
Outlook δπηιεϊ μβαι ϊηζιεϊ δηαψδ μωπϊ 2006 ιπϊπε αωιηϊ δεεςιγδ (τψθιν μδμο).
γιαιγπγ
γιψχθεψιεο δηαψδ, αιωιαϊε αιεν 9 αξΰι, 2006, δλψιζ ςμ ϊωμεν γιαιγπγ αξζεξο αβιο δψαςεο δψΰωεο ωμ ωπϊ 2006, αωιςεψ ωμ 0.34 ω"η μξπιδ (λ- 7.6 ’ ςμ τι ωςψ δγεμψ α- 9 αξΰι, 2006). διεν δχεας ιδιδ α- 16 αξΰι, 2006 ειεν δϊωμεν πχας μ- 31 αξΰι, 2006. ωιςεψ δξρ ωιπελδ αξχεψ ιδιδ 16%.
τψθι ωιηϊ δεςιγδ
δπδμϊ θας ϊχιιν ωιηϊ εςιγδ αιεν ψαιςι, 10 αξΰι, 2006, αωςδ 15:30 ωςεο ιωψΰμ (08:30 ωςεο πιε-ιεψχ) ΰωψ αδ ιιρχψε ϊεφΰεϊ δψαςεο δψΰωεο ωμ 2006. πιϊο μδΰζιο μωιηδ γψκ ΰϊψ δΰιπθψπθ ωμ θας, αλϊεαϊ : www.tevapharm.com. πιϊο ιδιδ μδΰζιο μωιγεψ ηεζψ ςγ μιεν 17 αξΰι, 2006 αηφεϊ (ωςεο πιε-ιεψχ) αΰϊψ δηαψδ, ΰε ςμ-ιγι ηιεβ 1-877-660-6853 μξηιιβιν αϊεκ ΰψδ"α ε- 201-612-7415 μξηιιβιν ξηευ μΰψδ"α. χεγ δλπιρδ μωιγεψ δηεζψ διπε ηωαεο ξρτψ (Account #) 3055 ε- ϊε δζιδει (ID#) διπε: 201219.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ, ιιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ εξεφψιν εεθψιπψιν, διπδ δηαψδ δξεαιμδ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο εαξψλζ ΰξψιχδ εαΰιψετδ. χψεα μ- 90% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |